Related Experiment Video

Updated: Aug 2, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

The relationship between plasma apolipoprotein A-IV levels and coronary heart disease

M W Manpuya1, J Guo, Y Zhao

  • 1Third Hospital, Beijing University Medical School, Beijing 100083, China.

Chinese Medical Journal
|January 10, 2002
PubMed

Insights

Lower plasma apolipoprotein A-IV (apoA-IV) levels are associated with coronary heart disease (CHD) and predict atherosclerosis severity. ApoA-IV may also influence triglyceride metabolism.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Lipid Metabolism

Background:

  • Coronary atherosclerosis is a leading cause of cardiovascular disease.
  • The role of apolipoprotein A-IV (apoA-IV) in coronary atherosclerosis requires further investigation.
  • Understanding novel biomarkers for cardiovascular risk is crucial for early detection and prevention.

Purpose of the Study:

  • To investigate the association between plasma apoA-IV levels and the presence and severity of coronary atherosclerosis.
  • To explore the relationship between apoA-IV and established cardiovascular risk factors.

Main Methods:

  • Plasma apoA-IV levels were measured using ELISA in 181 patients undergoing coronary angiography (CAG).
  • Patients were categorized into coronary heart disease (CHD) and control groups based on CAG findings.
  • Atherosclerosis severity was quantified using stenosis scoring; logistic regression analyses were employed.

Main Results:

  • Plasma apoA-IV levels were significantly lower in patients with CHD compared to controls.
  • A weak negative correlation was observed between apoA-IV levels and the severity of coronary atherosclerosis.
  • ApoA-IV emerged as a relatively independent risk factor for CHD and showed a positive correlation with triglyceride levels.

Conclusions:

  • Plasma apoA-IV may serve as a valuable predictor for coronary heart disease and the severity of coronary atherosclerosis.
  • ApoA-IV potentially plays a significant role in triglyceride metabolism.
  • Further research into apoA-IV's clinical utility in cardiovascular risk assessment is warranted.
Abstract

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients09:09

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients

Published on: April 3, 2026

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...